Loading clinical trials...
Loading clinical trials...
A Phase 2, Open Label, Study of VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL), (AIN2, AIN3, PAIN2, PAIN3) in Individuals That Are Seronegative for Human Immunodeficiency Virus (HIV)-1/2
Conditions
Interventions
VGX-3100
CELLECTRA™ 5PSP
Locations
3
United States
Howard Brown Health (HBH)-Sheridan
Chicago, Illinois, United States
Laser Surgery Care
New York, New York, United States
Clinique de Recherche en Sante
Québec, Quebec, Canada
Start Date
May 15, 2018
Primary Completion Date
June 16, 2020
Completion Date
May 26, 2021
Last Updated
July 14, 2023
Lead Sponsor
Inovio Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions